Arginyl-Glutamine
Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
For research use only. We do not sell to patients.
- CAS No.: 2483-17-2
- Formula: C11H22N6O4
- Molecular Weight:302.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
IC50 & Target
VEGF[1]
In Vitro
Arginyl-Glutamine (0.5-1.5 mM; 48 h) results in a statistically significant dose-dependent decrease soluble VEGF expression into the culture medium in human RPE cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL6/J mouse pups, oxygen-induced retinopathy (OIR) model[1]
-
Dosage:1.0, 2.5, or 5 g/kg per day
-
Administration:Intraperitoneal injection, twice daily
-
Result:Significantly decreased preretinal nuclei. Reduced neovascular tufts and vascular leakage in retinal vessels. Reduced preretinal neovascularization by 82% ± 7% and reduced VEGF mRNA by 64% ± 9% at 5 g/kg per day.
Chemical Information
-
CAS No. 2483-17-2
-
Molecular Weight 302.33
-
Formula C11H22N6O4
-
Synonyms
H-Arg-Gln-OH
-
Sequence
Arg-Gln
-
Sequence Shortening
RQ
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)